Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aeterna Zentaris Inc. (AEZS)

3.73   0.05 (1.36%) 01-27 15:59
Open: 3.74 Pre. Close: 3.68
High: 3.8 Low: 3.66
Volume: 9,774 Market Cap: 18(M)

Technical analysis

as of: 2023-01-27 4:42:19 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 4.59     One year: 5.36
Support: Support1: 3.28    Support2: 2.89
Resistance: Resistance1: 3.93    Resistance2: 4.59
Pivot: 3.72
Moving Average: MA(5): 3.74     MA(20): 3.6
MA(100): 3.8     MA(250): 5.43
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 68.5     %D(3): 73.4
RSI: RSI(14): 55.9
52-week: High: 11  Low: 0.16
Average Vol(K): 3-Month: 15 (K)  10-Days: 16 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AEZS ] has closed below upper band by 48.4%. Bollinger Bands are 51.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.8 - 3.83 3.83 - 3.85
Low: 3.61 - 3.64 3.64 - 3.66
Close: 3.69 - 3.74 3.74 - 3.77

Company Description

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Headline News

Tue, 17 Jan 2023
Aeterna Zentaris Provides Business Update and Outlines Key ... - GlobeNewswire

Tue, 10 Jan 2023
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event - Financial Post

Thu, 03 Nov 2022
Aeterna Zentaris Reports Third Quarter 2022 Financial Results - GlobeNewswire

Mon, 29 Aug 2022
Aeterna Zentaris Set to Regain Full Rights to Macrilen ... - GlobeNewswire

Mon, 18 Jul 2022
Aeterna Zentaris Announces Effective Date of Share Consolidation - GlobeNewswire

Tue, 21 Jun 2022
Aeterna Zentaris Announces Results of Annual Meeting of ... - GlobeNewswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 5 (M)
Shares Float 5 (M)
% Held by Insiders 0.3 (%)
% Held by Institutions 0.6 (%)
Shares Short 95 (K)
Shares Short P.Month 100 (K)

Stock Financials

EPS -0.08
EPS Est Next Qtl -0.26
EPS Est This Year -1.02
EPS Est Next Year -0.29
Book Value (p.s.) 10.18
Profit Margin (%) 0
Operating Margin (%) -349.9
Return on Assets (ttm) -12.1
Return on Equity (ttm) -24.1
Qtrly Rev. Growth 76.8
Gross Profit (p.s.) 1.06
Sales Per Share 0.84
EBITDA (p.s.) -2.96
Qtrly Earnings Growth 0
Operating Cash Flow -13 (M)
Levered Free Cash Flow -8 (M)

Stock Valuations

PE Ratio -47.22
PEG Ratio 0
Price to Book value 0.36
Price to Sales 4.41
Price to Cash Flow -1.44

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.